| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 05/18/2007 | WO2007003411A3 Kinin antagonists for treating bladder dysfunction |
| 05/18/2007 | WO2007000601A3 Gene regulation |
| 05/18/2007 | WO2007000036A3 Use of mas g-protein-coupled receptor agonists and antagonists as apoptotic activity modulators for prevention and treatment of diseases |
| 05/18/2007 | WO2006131749A3 Scaffold |
| 05/18/2007 | WO2006116702A3 Inducible nitric oxide synthase binds, s-nitrosylates, and activates cyclooxygenase-2 |
| 05/18/2007 | WO2006114308A3 Carrier for targeting nerve cells |
| 05/18/2007 | WO2006114105A3 Use of modified factor vii for treating bleeding |
| 05/18/2007 | WO2006112703A3 Induction of omega-oxidation of fatty acids by cytochrome p450 for counteracting fatty acid accumulation |
| 05/18/2007 | WO2006110577A3 Use of fril proteins for reducing the production of pro-inflammatory cytokines |
| 05/18/2007 | WO2006110551A3 Pharmaceutical formulations comprising incretin peptide and aprotic polar solvent |
| 05/18/2007 | WO2006103118A3 Therapeutic use of scin, a staphylococcal complement inhibitor in inflammatory diseases |
| 05/18/2007 | WO2006099261A3 Potent and specific immunoproteasome inhibitors |
| 05/18/2007 | WO2006042848A9 Growth hormone conjugates |
| 05/18/2007 | WO2006042152A3 Vasoactive intestinal polypeptide pharmaceuticals |
| 05/18/2007 | WO2006039588A3 Devices and methods for integrated continuous manufacturing of biological molecules |
| 05/18/2007 | WO2006032216A3 Peptides and apl-type derivatives of hsp60 and pharmaceutical compositions |
| 05/18/2007 | WO2006029487A8 Platelet factor 4 variant 1 (pf4var1) related inhibitors of angiogenesis |
| 05/18/2007 | WO2006025057A8 Use of il-6 in vascular complications |
| 05/18/2007 | WO2006020372A3 Enzymatic modification of glycopeptides |
| 05/18/2007 | WO2005072126A3 Antibodies for inhibiting blood coagulation and methods of use thereof |
| 05/18/2007 | WO2005016241A3 Synthetic chemokine receptor ligands and methods of use thereof |
| 05/18/2007 | WO2004103275A3 Compositions and methods for the preparation of human growth hormone glycosylation mutants |
| 05/18/2007 | WO2004022593A8 Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules |
| 05/18/2007 | WO2004011024A8 Pharmaceutical active ingredient preparations and medicaments that contain thrombin or have a thrombin-generating capacity |
| 05/18/2007 | WO2003077872A3 Cell surface tropomyosin as a target of angiogenesis inhibition |
| 05/18/2007 | WO2003076594A3 Genomic screen for epigenetically silenced tumor suppressor genes |
| 05/18/2007 | WO2000040740A3 Gene therapy to promote angiogenesis |
| 05/18/2007 | CA2634181A1 Human growth hormone patch formulations |
| 05/18/2007 | CA2629519A1 Improved variants of pigment epithelium derived factor and uses thereof |
| 05/18/2007 | CA2629376A1 Inhibitors of parp activity and uses thereof |
| 05/18/2007 | CA2629113A1 Metal-binding therapeutic peptides |
| 05/18/2007 | CA2629084A1 Compounds for enzyme inhibition |
| 05/18/2007 | CA2628876A1 R-ras activity in vascular regulation |
| 05/18/2007 | CA2628816A1 Modulation of il-2 production by t-bet |
| 05/18/2007 | CA2628472A1 Surfactant protein-d for prevention and treatment of lung infections and sepsis |
| 05/18/2007 | CA2628451A1 Methods for promoting neurite outgrowth and survival of dopaminergic neurons |
| 05/18/2007 | CA2628241A1 Glucagon analogs exhibiting physiological solubility and stability |
| 05/18/2007 | CA2628216A1 Heparan sulfate glycosaminoglycan lyase and uses thereof |
| 05/18/2007 | CA2628051A1 Treatment of obesity and related disorders |
| 05/18/2007 | CA2626859A1 Tnf-alpha blocker treatment for enterocolitis associated with immunostimulatory therapeutic antibody therapy |
| 05/18/2007 | CA2626675A1 Biosynthetic polypeptide fusion inhibitors |
| 05/18/2007 | CA2624393A1 Use of complement pathway inhibitors to treat ocular diseases |
| 05/17/2007 | US20070113304 Antifreeze proteins isolated from forage grasses and methods for their use |
| 05/17/2007 | US20070112179 Novel compounds |
| 05/17/2007 | US20070112175 Determining drug resistance |
| 05/17/2007 | US20070111982 Calcitonin Gene-Related Peptide, CGRP; treatment of migraine and cluster headache; 2,5-dioxo-3',4'-dihydro-spiro(imidazolidine-4,2'(1'H)-naphthalene)-6'-carboxamides |
| 05/17/2007 | US20070111961 Dbait and uses thereof |
| 05/17/2007 | US20070111949 Modulating nitric oxide acitivity with glutathione-dependent formaldehyde dehydrogenase (GS-FDH); for treatment of asthma and impotency, angina, hypertension, and cancer; enzyme inhibitors |
| 05/17/2007 | US20070111948 Agent derived from tortoise spleen stimulating mammalian hemopoiesis |
| 05/17/2007 | US20070111947 Fibrin targeted therapeutics |
| 05/17/2007 | US20070111946 Bioactive peptides and peptide derivatives of parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHrP) |
| 05/17/2007 | US20070111945 Use of corticotroph-derived glycoprotein hormone to treat inflammation and potentiate glucocorticoid action |
| 05/17/2007 | US20070111944 Purification of vascular endothelial growth factor-B |
| 05/17/2007 | US20070111943 Tetrodotoxin-resistant sodium channel alpha subunit |
| 05/17/2007 | US20070111942 For detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells |
| 05/17/2007 | US20070111941 Cytokine receptor zalpha11 |
| 05/17/2007 | US20070111940 Peptide agonists of GLP-1 activity |
| 05/17/2007 | US20070111939 Human interleukin-11 receptor |
| 05/17/2007 | US20070111938 Peptide pharmaceutical compositions |
| 05/17/2007 | US20070111937 Use of fibrous tissue inducing proteins for hernia repair |
| 05/17/2007 | US20070111936 Complex of alpha-fetoprotein and inducers of apoptosis for the treatment of cancer |
| 05/17/2007 | US20070111935 Fibroblast growth factors; endothelial growth factors; stem cells; gene therapy; creatine kinase |
| 05/17/2007 | US20070111934 Procaspase 1 activation inhibitor |
| 05/17/2007 | US20070111933 Diagnosis and treatment methods related to aging, especially of liver |
| 05/17/2007 | US20070111932 Method of enhancing and/or inducing neuronal migration using erythropoietin |
| 05/17/2007 | US20070111931 Compositions and methods for promoting wound healing and tissue repair |
| 05/17/2007 | US20070111930 Process for preparing vapreotide |
| 05/17/2007 | US20070111929 Methods for the treatment of anxiety and for identification of anxiolytic agents |
| 05/17/2007 | US20070111928 Didemnin analogs and fragments and methods of making and using them |
| 05/17/2007 | US20070111927 Peptoid compounds |
| 05/17/2007 | US20070111926 Conjugation of peptides |
| 05/17/2007 | US20070111285 Human skeletal muscle-specific ubiquitin-conjugating emzyme |
| 05/17/2007 | US20070111266 Antibodies to murine zcytor17 ligand |
| 05/17/2007 | US20070111252 Alcadeins and amyloid precursor protein co-localization for use as evaluative and prognostic tools in monitoring dementia and nervous system degeneration |
| 05/17/2007 | US20070111222 Nucleic acid aptamer-based compositions and methods |
| 05/17/2007 | US20070111214 20685, 579,17114, 23821, 33894 and 32613, novel human transporters |
| 05/17/2007 | US20070110828 Administering a NF- kappa B inhibitor in conjunction with the administration of a chemotherapeutic agent, whereby the cytotoxic effect of said chemotherapeutic agent is increased |
| 05/17/2007 | US20070110818 Milk fractions and milk preparations for treating and/or preventing cox-2 mediated diseases |
| 05/17/2007 | US20070110814 Bioactive polypeptide conjugated to the sulfate group; sustained release; alginate sulfate or sulfated hyaluronan conjugated to e.g. insulin, glatiramer acetate, antithrombin III, interferon gamma , IGF, somatostatin, luteinizing hormone-releasing hormone, erythropoietin, interleukins |
| 05/17/2007 | US20070110813 Polycation-polyanion complexes, compositions and methods of use thereof |
| 05/17/2007 | US20070110811 Methods for reducing the mitogenicity of lectin compositions |
| 05/17/2007 | US20070110809 Stabilised compositions |
| 05/17/2007 | US20070110804 Drug polymer complexes |
| 05/17/2007 | US20070110785 Medical devices with proteasome inhibitors for the treatment of restenosis |
| 05/17/2007 | US20070110775 Phospholipid gel compositions for delivery of aptamers and methods of treating conditions using same |
| 05/17/2007 | US20070110769 Clostridial toxin derivatives and methods for treating pain |
| 05/17/2007 | US20070110766 Proteinase K resistant surface protein of neisseria meningitidis |
| 05/17/2007 | US20070110763 Polypeptides of streptococcus pyogenes |
| 05/17/2007 | US20070110760 Methods and compositions targeting viral and cellular ITAM motifs, and use of same in identifying compounds with therapeutic activity |
| 05/17/2007 | US20070110758 Method for inhibiting bacterial colonisation |
| 05/17/2007 | US20070110756 Method for modulating P53 activity via methylation |
| 05/17/2007 | US20070110755 Vascular endothelial cell growth factor antagonists |
| 05/17/2007 | US20070110749 Centrosome proteins and uses thereof |
| 05/17/2007 | US20070110748 Fibronectin binding protein compositions and methods of use |
| 05/17/2007 | US20070110746 Pharmaceutical composition for treatment of immunological disorders |
| 05/17/2007 | US20070110745 Antagonists of TWEAK and of TWEAK receptor and their use to treat immunological disorders |
| 05/17/2007 | US20070110744 Lymphatic and blood endothelial cell genes |
| 05/17/2007 | US20070110742 Recombinant peptide vector comprising the gene for treatment for autoimmune diseases |
| 05/17/2007 | US20070110741 Single-wall carbon nanotube-egg white protein composite and preparation thereof |
| 05/17/2007 | US20070110740 Composition and methods for tissue preservation |